The DOI matches its Crossref record; 499 of the 502 references it cites were found in a registry or an index.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Open accessAbstract
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance document reflects many advances in the field pertinent to any practitioner caring for patients with NAFLD and emphasizes advances in noninvasive risk stratification and therapeutics. A separate guideline focused on the management of patients with NAFLD in the context of diabetes has been written jointly by the American Association of Clinical Endocrinology and AASLD.2 Given the significant growth in pediatric NAFLD, it will not be covered here to allow for a more robust discussion of the diagnosis and management of pediatric NAFLD in the upcoming AASLD Pediatric NAFLD Guidance. A “Guidance” differs from a “Guideline” in that it is not bound by the Grading of Recommendations, Assessment Development and Evaluation system. Thus, actionable statements rather than formal recommendations are provided herein. The highest available level of evidence was used to develop these statements, and, where high-level evidence was not available, expert opinion was used to develop guidance statements to inform clinical practice. Key points highlight important concepts relevant to understanding the disease and its management. The most profound advances in NAFLD relevant to clinical practice are in biomarkers and therapeutics. Biomarkers and noninvasive tests (NITs) can be used clinically to either exclude advanced diseases or identify those with a high probability of cirrhosis.3,4 NIT “cut points” vary with the populations studied, underlying disease severity, and clinical setting. Those proposed in this guidance are meant to aid decision-making in the clinic and are not meant to be interpreted in isolation. Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest. Although the definitive diagnosis and staging of NASH remain linked to histology, noninvasive tools can now be used to assess the likelihood of significant fibrosis, predict risk of disease progression and decompensation, make management decisions, and, to some degree, assess response to treatment. There is an ongoing debate over the nomenclature of fatty liver disease, which had not been finalized at the time this guidance was published. At the culmination of a rigorous consensus process, it is intended that any formal change in nomenclature will advance the field without a negative impact on disease awareness, clinical trial endpoints, or the drug development/approval process. Furthermore, it should allow for the emergence of newly recognized disease subtypes to address the impact of disease heterogeneity, including the role of alcohol, on disease progression and response to therapy. Input from patients has been central to all stages of the consensus process to ensure the minimization of nomenclature-related stigma. DEFINITIONS NAFLD is an overarching term that includes all disease grades and stages and refers to a population in which ≥5% of hepatocytes display macrovesicular steatosis in the absence of a readily identified alternative cause of steatosis (eg, medications, starvation, monogenic disorders) in individuals who drink little or no alcohol (defined as < 20 g/d for women and <30 g/d for men). The spectrum of disease includes NAFL, characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation, and NASH, which is additionally characterized by the presence of inflammation and cellular injury (ballooning), with or without fibrosis, and finally cirrhosis, which is characterized by bands of fibrous septa leading to the formation of cirrhotic nodules, in which the earlier features of NASH may no longer be fully appreciated on a liver biopsy. UPDATE ON EPIDEMIOLOGY AND NATURAL HISTORY The prevalence of NAFLD and NASH is rising worldwide in parallel with increases in the prevalence of obesity and metabolic comorbid disease (insulin resistance, dyslipidemia, central obesity, and hypertension).5,6 The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population7–9 and varies with the clinical setting, race/ethnicity, and geographic region studied but often remains undiagnosed.10–14 The associated economic burden attributable to NASH is substantial.15–17 The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.14 This study also highlights that since the publication of a prior prospective prevalence study,18 the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased >2-fold. This is supported by the projected rise in NAFLD prevalence by 2030, when patients with advanced hepatic fibrosis, defined as bridging fibrosis (F3) or compensated will the proj
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on this, it seems reasonable to conclude that should patients continue to complete guideline-based amounts of aerobic exercise over a longer duration, fibrosis improvement may follow [35, 36].”
From Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interventions in diet and physical activity are considered to be the cornerstone of management in the whole MASLD spectrum [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there is no consensus on the optimal diet for treating MASLD, the EASL-EASD-EASO guidelines recently recommended the MD as the preferred option [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current guidelines recommend weight loss through dietary modifications, increased physical activity, or both combined in MASLD patients [7, 11, 12].”
The cited source says what the claim attributes to it.
In the citing paper
“Various scienti fi c societies have recommended clinical care pathways with an emphasis on the use of non-invasive tests (NITs) and the liaison between primary care/non-hepatology and hepatology settings.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [126]
In the citing paper
“GLP-1RA-based drugs have been proven beneficial to some extent in dedicated trials and should be considered in patients with obesity and/or T2D and metabolic dysfunction-associated steatohepatitis (MASH)90.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,597
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,002
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 9
Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B
Huynh, C.-N. (2024) · American Journal of Cancer Research · doi:10.62347/ljrg3048 · Cited by 9
Jiao, B., Wang, B., Liu, B., Zhao, J., & Zhang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1468476 · Cited by 9
Romano, J., Burnside, J., Sebastiani, G., Ramji, A. S., Patel, K., Swain, M. G., & Saeed, S. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101757 · Cited by 9
Taylor, L. C., Arthur, G., Cruz, M. D. C., Stec, D. E., & Badmus, O. O. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4040052 · Cited by 12
“…of Liver Diseases, European Society of Cardiologists, European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), and American Heart Association have all strongly recommended the integration of CVD risk assessments in all patients with MASLD [16–18].”
Inukai, Y., Ito, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shimizu, T., Hattori, M., Takeyama, T., et al. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13325 · Cited by 9
“NASH or metabolic-associated steatohepatitis (MASH) was diagnosed based on the presence of steatosis and centrilobular ballooning, Mallory–Denk bodies, or steatosis and centrilobular pericellular, pericellular/perisinusoidal, or bridging fibrosis [12, 18].”
BMI trajectories are associated with NAFLD and advanced fibrosis via aging-inflammation mediation
Peng, H., Zhao, Z., Gong, J.-P., & He, K. (2025) · BMC Public Health · doi:10.1186/s12889-025-21322-5 · Cited by 9
“NAFLD was defined as CAP ≥ 288 dB/min after exclusions [12].”
John, B. V., Bastaich, D., Mezzacappa, C., Ferreira, R., Hentschel, A., Samos, A., Mahmud, N., Taddei, T. H., Kaplan, D. E., Serper, M., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003321 · Cited by 10
Khan, F. A., Dsouza, S., Khamis, A. H., Abdul, F., Farooqi, M. H., Sulaiman, F., Mulla, F., Alawadi, F., Hassanein, M. M., & Bayoumi, R. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09348-2 · Cited by 12
Sun, Y., Hu, D., Yu, M., Liang, S.-B., Zheng, Y., Wang, X., & Tong, G. (2025) · Clinical Epidemiology · doi:10.2147/clep.s501445 · Cited by 9
Alqahtani, S. A., AlAhmed, R. S., AlOmaim, W. S., Alghamdi, S. A., Al-hamoudi, W., Bzeizi, K. I., Albenmousa, A. H., Aghemo, A., Pugliese, N., Hassan, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317929 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“By contrast, glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors either induce weight loss or at least have a neutral effect on weight [8,26].”
van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., le Cessie, S., Numans, M. E., Pijl, H., & Lamb, H. J. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.02.017 · Cited by 9
Rautou, P., Chotkoe, S., Biquard, L., Wettstein, G., van der Graaff, D., Liu, Y., Man, J. D., Casteleyn, C. R., Thys, S., Vos, W. H. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101366 · Cited by 14
Self-citationAllen, A. M., Kim, W. R., Carrieri, P., Canning, R. E., Ou, F., Benson, J. T., Olson, J. L., Venkatesh, S. K., Li, J., Yin, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001311 · Cited by 9
Kaya, E., Vilar‐Gómez, E., Vuppalanchi, R., & Yilmaz, Y. N. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101907 · Cited by 9
Oxyntomodulin - past, present and future
Holst, J. J., & ROSENKILDE, M. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171393 · Cited by 12
“Today the prevalence of steatotic liver lesions has increased dramatically and steatotic diseases of the liver are now the most numerous and important diseases of the liver [53].”
John, K., Franck, M., Geier, A., Schattenberg, J. M., Schulze-Osthoff, K., Bantel, H., Demir, M., Rau, M., Sowa, J.-P., & Wedemeyer, H. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.014 · Cited by 9
Shang, D.-F., Xu, W.-Q., Zhao, Q. Y., Zhao, C., Wang, S.-Y., Han, Y., Li, H., Liu, M., & Zhao, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107754 · Cited by 10
Choi, Y. J., Park, J.-H., Cho, H.-I., Shin, M., & Nah, E. (2025) · Metabolites · doi:10.3390/metabo15050299 · Cited by 10
“FIB-4 1.30 has an NPV of 90% for excluding advanced fibrosis, making it suitable for low-risk management in primary care, focusing on obesity and CVD prevention [51].”
InfluentialLi, G., Wong, V. W., Chan, R., Sin, D. M.-C., Chu, C. W., Wong, V., Cheung, C., Lam, S., Lin, H., Yeung, S. S. Y., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00032-3 · Cited by 10
Verdan, S., Torri, G. B., Marcos, V. N., Moreira, M. H. S., Defante, M. L. R., Fagundes, M. D. C., de Barros, E. M. J., Dias, A. B., Shen, L., & Altmayer, S. (2025) · European Radiology · doi:10.1007/s00330-025-11652-8 · Cited by 11
Grueso-Navarro, E., & Lucendo, A. J. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2514605 · Cited by 9
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 12
“Weight loss is currently the cornerstone intervention for MASLD and NASH [38].”
Bołdys, A., Bułdak, Ł., Nicze, M., & Okopień, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125883 · Cited by 9
“The current imaging gold standard—MRI proton density fat fraction (MRI-PDFF)—offers excellent precision but is even less accessible due to cost and logistical barriers [25,26].”
James, L., Diamond, C., Al‐Mossawi, H., Andersson, A., Pandya, P., Shumbayawonda, E., Firouzabadi, L. I., Watson, L., Savage, L. J., Thomaides-Brears, H. B., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf344 · Cited by 11
Zhang, D., Zhang, D., Pawar, S., Shera, S., Hernandez, L., Jacobs, J. P., & Dong, T. S. (2025) · Nutrients · doi:10.3390/nu17132145 · Cited by 11
Jamal, F., Elshaer, A., Odeh, N. B., Alatout, M. H., Shahin, T. B., Worden, A. R., Albunni, H. N., Lizaola-Mayo, B. C., Jayasekera, C., Chascsa, D., et al. (2025) · Life · doi:10.3390/life15081306 · Cited by 12
“First-line treatment for MASLD primarily involves lifestyle interventions such as weight reduction, increased physical activity, and dietary changes [7].”
Liu, Q., Luan, H., Duan, Z., Ai, J., Wang, Y., & Chen, P. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1660065 · Cited by 15
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 12
Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM
Wu, J., Chang, H.-Y., Yu, T., & Lin, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112918 · Cited by 11
Schiborn, C., Hu, F. B., Stefan, N., & Schulze, M. B. (2026) · Nature Communications · doi:10.1038/s41467-026-69738-w · Cited by 10
“…urinary system: self-reported chronic urinary incontinence, 7) liver: hepatic fi brosis (FIB-4 index 35,36 , increased NAFLD Fibrosis Score 19,35 , or increased hepatic stiffness measured by vibration-controlled transient elastography (FibroScan®)), 8) musculoskeletal: self-reported…”
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Armandi, A., Michel, M. S., Gjini, K., Emrich, T., Bugianesi, E., & Schattenberg, J. M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2242779 · Cited by 9
“While the broad field appreciates the positive definition and reduction of stigma, the lack of a clear definition of metabolic risks has more recently led to the context of steatotic liver disease (SLD) as an overarching term [16].”
BackgroundVujović, A., Isakovic, A. M., Misirlić‐Denčić, S., Juloski, J. T., Mirković, M., Cirkovic, A. M., Djelic, M. N., & Milošević, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512483 · Cited by 9
Serum biomarkers for liver fibrosis assessment
Maroto‐García, J., Álvarez, A. M., de Pedro, M. P. S., Soto, A. B., & González, Á. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0081 · Cited by 12
Boeriu, A. M., Dobru, D. E., & Fofiu, C. (2023) · Life · doi:10.3390/life13122262 · Cited by 9
“According to EASL and AASLD guidelines, low-risk patients (FIB-4 1.3) can be managed in primary care, and fibrosis scores should be done periodically (every 1–2 years) for risk reassessment [149,151].”
BackgroundMethodInfluentialVelacur ACE outperforms FibroScan CAP for diagnosis of MASLD
Loomba, R. S., Ramji, A. S., Hassanein, T., Yoshida, E. M., Pang, E., Schneider, C., Curry, M. P., & Afdhal, N. H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000402 · Cited by 9
“…liver biopsy remains the gold standard for the diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-associated stea-tohepatitis (MASH), there are issues with morbidity [1,2] and misclassification due to sampling and interobserver and intraobserver variation.”
BackgroundMethodSelf-citationUse of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
Rashu, E. B., Werge, M. P., Hetland, L. E., Thing, M., Nabilou, P., Kimer, N., Junker, A. E., Jensen, A.-S. H., Nordestgaard, B. G., Stender, S., et al. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102389 · Cited by 9
Alfieri, C., Molinari, P., Cinque, F., Vettoretti, S., Cespiati, A., Bignamini, D., Nardelli, L., Fracanzani, A. L., Castellano, G., & Lombardi, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147728 · Cited by 10
“The American Association for the Study of the Liver has recently proposed an algorithm for the screening and referral of patients with suspected liver disease by combining FIB-4 and Fibroscan, which can also be applied to the diabetic population (Figure 7) [63].”
BackgroundMethodInfluentialFarzi, M., McGenity, C., Cratchley, A. L., Leplat, L., Bankhead, P., Wright, A. I., & Treanor, D. E. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110049 · Cited by 9
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Borozan, S., Vujošević, S., Mikhailidis, D. P., & Muzurović, E. M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611340703240809044916 · Cited by 9
Jaroenlapnopparat, A., Thompson, C. C., & Jirapinyo, P. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06668-2 · Cited by 8
Koschade, S. E., Moser, L. M., Sokolovskiy, A., Michael, F. A., Serve, H. L., Brandts, C., Finkelmeier, F., Zeuzem, S., Trebicka, J., Ferstl, P. G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134373 · Cited by 9
Chaturvedi, S., Tripathi, D., Vikram, N. K., Madhusudhan, K. S., Pandey, R. M., & Bhatia, N. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.02.001 · Cited by 8
Smati, S., Wargny, M., Boursier, J., Moulin, P., Filippo, M. D., & Cariou, B. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.031 · Cited by 8
de Oliveira, L. D. R. P., Ribeiro, T. C. D. R., Júnior, C. A. M., Barra, M. A. D. L., Silva, M. H. G., Shafee, L. P., Zacarias, S. M., Campos, L. D. C., Valério, H. M. G., & Chebli, J. M. F. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20231321 · Cited by 8
“Intermediate values were considered indeterminate and nondiagnostic 16,17 .”
BackgroundLiu, S., Jiang, X., Fu, J., Zhong, V. W., Zhong, V. W., & Qi, X. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.005 · Cited by 8
Schreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.002 · Cited by 8
Flavin, B. M. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.9-a.s1 · Cited by 8
Kwan, S., Gonzales, K. A., Jamal, M. A., Stevenson, H. L., Tan, L., Lorenzi, P. L., Futreal, P. A., Hawk, E. T., McCormick, J. B., Fisher‐Hoch, S. P., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2399260 · Cited by 9
“Based on the literature and AASLD Practice Guidance, 20,21 liver steatosis was defined as CAP ≥ 268.”
MethodGoyal, T., Song, M. W., Suresh, D., Jasty, V. S. J., Urias, E., Wijarnpreecha, K., Wong, Y. J., & Chen, V. L. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08683-4 · Cited by 7
“It is characterized by a disease spectrum that ranges from simple steatosis to steatohepatitis, fibrosis, and cirrhosis, and the later stages of its indolent course can manifest with progression to hepatic decompensation, hepatocellular carcinoma, and liver-related death [3].”
InfluentialJeon, J. Y., Ayyar, V. S., Ouchi, S., Fabbrini, E., Koshkina, A., Prusakiewicz, J. J., Dallas, J., Yang, T., Jian, W., Kang, L., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6174 · Cited by 9
Comi, L., Giglione, C., Klinaku, F. T., Pialorsi, F., Tollemeto, V., Zurlo, M., Seneci, A., & Magni, P. (2024) · Food Frontiers · doi:10.1002/fft2.535 · Cited by 8
Lam, B. P., Bartholomew, J., Bau, S., Gilles, H., Keller, A., Moore, A., Nader, K., Richards, L., Henry, L. L., & Younossi, Z. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002140 · Cited by 8
“In 16 – 18 Noncirrhotic HCC “ case-fi nding ” should be individualized by clinicians based on the presence of other risks, such as the family history of HCC, and other HCC risks.”
van Kleef, L. A., Pustjens, J., Janssen, H. L. A., & Brouwer, W. P. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102512 · Cited by 8
“…the EASL and AASLD guidelines, we used the LSM $ 8 kPa and $ 12 kPa as clinically relevant cut-offs, rather than the categories used for LRS. 6,21 Second, no follow-up data were available on liver-related events, and further validation of the associations with adverse outcomes could not be…”
Piñar-Gutiérrez, A., Quintana‐Gallego, E., Remón-Ruiz, P., Pizarro, Á., González-Navarro, I., Jiménez‐Sánchez, A., García-Rey, S., Roque-Cuéllar, M. D. C., Gato, S., Domínguez, I., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.02.007 · Cited by 8
Wang, S., Xu, Z., Wang, Z., Yi, X., & Wu, J. (2025) · BMC Genomics · doi:10.1186/s12864-025-11377-4 · Cited by 8
“MASLD is an umbrella term encompassing a continuum of liver conditions, extending from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) [4].”
Liu, W., Sun, M. J., Zhang, H., Wang, W., Song, J., Wang, M.-Y., Wang, C., & Sun, H.-M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141660 · Cited by 10
Wang, H., Ye, J., Chen, Y., Sun, Y., Gong, X., Deng, H., Dong, Z., Xu, L., Li, X., & Zhong, B. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03778-2 · Cited by 9
“…steatotic liver disease (MASLD), recently renamed from its previous designation as metabolic-associated fatty liver disease (MAFLD) and/or nonalcoholic fatty liver disease (NAFLD) in 2023, is the most prevalent liver disease, affecting over one-third of the global population [1].”
Laine, S., Sjöros, T., Garthwaite, T., Honka, M., Löyttyniemi, E., Norha, J., Eskola, O., Koivumäki, M., Vähä‐Ypyä, H., Sievänen, H. T., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00446.2024 · Cited by 9
Zhang, Y., Luo, P., Tang, Y.-N., Wang, J., Gao, S., Fan, Y., & Wang, K. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00942-z · Cited by 8
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 10
“Relatedly, in a small open-label study, vitamin E was associated hemorrhagic stroke and prostate cancer [88], vitamin E may be beneficial www.co-hivandaids.com MASLD-HIV.”
Zhong, H., Liu, C., Huang, Z., Tan, P., Chen, H., & Fu, W. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.02.003 · Cited by 9
Hartman, M. L., Loomba, R. S., Lawitz, E., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Tang, Y., Brouwers, B., Bunck, M. C. M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101472 · Cited by 9
Self-citationTrifylli, E.-M., Angelakis, A., Kriebardis, A. G., Papadopoulos, N., Fortis, S. P., Pantazatou, V., Koskinas, J. S., Kranidioti, H., Koustas, E., Sarantis, P., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i22.106937 · Cited by 8
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 11
“Multidisciplinary teams composed of hepatologists, cardiologists, endocrinologists, physiotherapists, dietitians, and psychologists must be involved in treating patients with MASLD [21].”
Karjoo, S., Braglia‐Tarpey, A., Chan, A. P., Germán, A. G. A., Herdes, R. E., Pai, N., Velez, D. S., Whitehead, B. A., Quirós‐Tejeira, R. E., & Duro, D. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70099 · Cited by 9
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 8
“Importantly, it has been shown that GLP-1 RAs can reduce the risk of hepatic and cardiovascular related complications [75,76].”
Hashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 8
“The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are typically elevated in MASLD, but they lack sensitivity and specificity in isolation [14].”
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 12
“Similar to the recommendations for weight loss and dietary modification, both North American and European guidelines focus on exercise as a key tenet in the management of MASLD [17,91].”
InfluentialMartin, C. M. P., Polizzi, A., Alquier‐Bacquie, V., Huillet, M., Rives, C., Dauriat, C. J. G., Bruse, J., Melin, V., Naylies, C., Lippi, Y., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113221 · Cited by 8
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease
Rodríguez, S., Dahlem, M. L. F., Rossoni, C., Marroni, N. P., Marroni, C. A., & Fernandes, S. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108182 · Cited by 8
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 11
Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults
Brown, C. L., & Bajaj, J. S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003641.07 · Cited by 8
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 9
Tou, A. M., & Panganiban, J. A. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70242 · Cited by 9
Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today’s World
Jalil, S., Pagadala, M. R., Dunn, N., Blaney, H. L., Elfeki, M. A., Thakral, N., & Singal, A. K. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00713-7 · Cited by 8
Abbas, M. S., Dandamudi, M., Rehman, T., Faizan, M. A., Zahra, I., Mojica, J. C., Ahmed, M. M. A., Bai, K., Shakeel, I., Shahzad, Z., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01797-0 · Cited by 8
Lee, Y., & Lee, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-31289-3 · Cited by 8
“In accordance with established cutoffs from previous studies and clinical guidelines, participants were categorized into low ( 1.30) and intermediate/high (≥ 1.30) FIB-4 groups, reflecting a higher likelihood of significant liver fibrosis 31 .”
InfluentialLoomba, R. S., Clark, V., Mandorfer, M., Miravitlles, M., Brantly, M., Karpen, S. J., Krag, A. A., Kwo, P. Y., Rockey, D. C., Russo, M. W., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.12.012 · Cited by 8
Self-citationBlood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD
Huang, Y., Li, J., Song, S., Du, B., Cao, Y., Wang, Y., Fu, H., Zhou, T., Yu, S., Liu, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102522 · Cited by 9
Hsieh, M.-L., Su, T., Lin, Y., Chen, Y., Tung, C.-F., Huang, L., Wu, C.-H., Peng, Y., & Hsieh, V. C. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70259 · Cited by 8
Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD
Migni, A., Bartolini, D., Ceccarini, M. R., Galli, C., Cavaliere, G., Garetto, S., Lucci, J., & Galli, F. (2026) · Progress in Lipid Research · doi:10.1016/j.plipres.2026.101380 · Cited by 10
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 9
Self-citationTachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review
Tun, K. M., Noureddin, N., & Noureddin, M. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000066 · Cited by 8
Ciardullo, S., Muraca, E., Zerbini, F., & Perseghin, G. (2023) · Liver International · doi:10.1111/liv.15742 · Cited by 8
“32 33– 35 Nonetheless, data were limited to several longitudinal”
BackgroundCan liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155721 · Cited by 8
Kalligeros, M. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0840 · Cited by 8
“Nonalcoholic fatty liver disease (NAFLD) can manifest as simple hepatic steatosis, but it may progress to nonalcoholic steatohepatitis (NASH), severe fibrosis, and even cirrhosis [1].”
Zanini, B., Benini, F., Marullo, M., Simonetto, A., Rossi, A., Cavagnoli, P., Bonalumi, A., Marconi, S., Pigozzi, M. G., Gilioli, G., et al. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/8861126 · Cited by 11
“…for the diagnosis management of NAFLD, controlled attenuation parameter (CAP) provides a good semi-quantitative assessment of hepatic steatosis [28]; at the time of the study progress, no elastography instrument was available at the Department of Medicine, (removed for blind peer review).”
BackgroundFreer, C. L., George, E. S., Tan, S., Abbott, G., & Daly, R. M. (2024) · British Journal Of Nutrition · doi:10.1017/s0007114524000242 · Cited by 9
Kim, M., Ahn, S., Hur, N., Oh, S.-Y., & Son, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362391 · Cited by 9
Samala, N. R., Kulkarni, M., Lele, R. S., Gripshover, T. C., Wise, J. L., Rai, S. N., & Cave, M. C. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae106 · Cited by 10
Bur, R., Suwarto, S., Pohan, H. T., Prihartono, J., Harahap, A. R., Dewi, B. E., Sadikin, M., Rachman, A., & Yusuf, H. (2024) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-024-00230-3 · Cited by 8
Fetal body composition reference charts and sexual dimorphism using magnetic resonance imaging
Rabinowich, A., Avisdris, N., Yehuda, B., Vanetik, S., Khawaja, J., Graziani, T., Neeman, B., Wexler, Y., Specktor‐Fadida, B., Herzlich, J., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.10.004 · Cited by 8
Castillo, M. F., Salgado-Canales, D., Arrese, M. A., Francisco Barrera, M., & Mikhailidis, D. P. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611285401240110074530 · Cited by 7
Lee, J. H., Lee, H. S., Jeon, S., Lee, J., & Kwon, Y. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.01.200 · Cited by 8
Li, Y., Guo, Y., & Tan, S. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102320 · Cited by 8
Metadata
- Authors
- Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R.
- Affiliations
- University of Chicago (US)
- Saint Louis University School of Medicine, Saint Louis, Missouri, USA
- Virginia Commonwealth University (US)
- Mayo Clinic (US)
- University of Virginia (US)
- University of Florida Health (US)
- National Institutes of Health (US)
- University of California San Diego (US)
- Corresponding author
- Rinella, Mary E.
- ORCID
- Venue
- Hepatology
- Published
- 2023-03-17
- Volume
- 77
- Issue
- 5
- Pages
- 1797-1835
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10735173
- OpenAlex
- W4318923555
- Cited by
- 2,667
- References
- 502
- Citations by year
- 2026: 849 · 2025: 845 · 2024: 691 · 2023: 281
- FWCI
- 532.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- American Association for the Study of Liver Diseases
- NGM Biopharmaceuticals
- Novo Nordisk
- National Institutes of Health
- Allergan
- National Cancer Institute (ZICBC010685)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, non-invasive risk stratification, non-invasive tests, fibrosis staging, liver cirrhosis
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
